CIVILICA We Respect the Science
(ناشر تخصصی کنفرانسهای کشور / شماره مجوز انتشارات از وزارت فرهنگ و ارشاد اسلامی: ۸۹۷۱)

Serum Amyloid A (SAA) as Early Diagnosis of COVID-۱۹ Disease: A Systematic Review and Meta-Analysis

عنوان مقاله: Serum Amyloid A (SAA) as Early Diagnosis of COVID-۱۹ Disease: A Systematic Review and Meta-Analysis
شناسه ملی مقاله: JR_IJMM-17-2_001
منتشر شده در در سال 1401
مشخصات نویسندگان مقاله:

Iman Owliaee - Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
Nastaran Saadat - Department of Virology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Shahab Mahmoudvand - Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Hossein Vakilimofrad - Department of Medical Library and Information Sciences, School of Paramedicine, Hamadan University of Medical Sciences, Hamadan, Iran
Salman Khazaei - Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
Nastaran Ansari - Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Razieh Amini - Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
Farid Azizi Jalilian - Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

خلاصه مقاله:
Background and Aim: In December ۲۰۱۹, human-to-human transmission of respiratory illness (pneumonia) with fever and sputum was discovered in the respiratory tract, called COVID-۱۹. Serum amyloid A (SAA) is an acute-phase plasma protein that is considered to be diagnostically superior to CRP in pathological conditions such as viral diseases. Therefore, the study question in this review is whether SAA as an indicator is involved in the early diagnosis of COVID disease. Materials and Methods: To identify related studies, we systematically searched international databases, including PubMed, Scopus, Science Direct, Cochrane, Embase, Web of Science, and Google Scholar search engine, without restriction on time until June ۲۰۲۱. Also, the Reference list of relevant studies was reviewed separately to find all existing articles in this field. Summary standardized mean difference (SMD) was estimated using random effects meta-analysis. Results: A total of ۳۹۴ potentially relevant articles were identified from the initial search. After removing the duplicates and reading the title, abstract and full-text review, six studies were entered into the meta-analysis. There was a significant difference between the means of SSA among patients with a severe form of the disease compared to non-sever groups (SMD=-۰.۹۱, ۹۵% CI: ۱.۱۸-۱.۵۹, -۰.۲۳) and with the control group (SMD=۴.۶۸, ۹۵% CI: ۱.۱۸, ۸.۱۸). The Beggs and egger test results indicated no evidence of publication bias in the reported SMD. Conclusion: The result of our work indicates that SAA might potentially be used for the early diagnosis of COVID disease, but more studies are needed.

کلمات کلیدی:
Early Diagnosis, COVID-۱۹ disease, SAA, Serum amyloid A protein, پروتئین سرم آمیلوئید A, تشخیص زودهنگام, بیماری کووید ۱۹

صفحه اختصاصی مقاله و دریافت فایل کامل: https://civilica.com/doc/1690532/